JTK-853 

JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HCV polymerase^[1]
EC50: 0.38 μM (1a H77 HCV), 0.035 μM (1b Con1 HCV)^[1]

JTK-853 is a novel, non-nucleoside Hepatitis C Virus Polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively. When JTK-853 is incubated with the replicon cells for 48 h, it shows antiviral activity against genotype 1a H77 and 1b Con1 replicon cells with EC₉₀ values of 6.5±0.5 and 0.34±0.05 µM, respectively. At 10 µM, JTK-853 induces apparent Huh-7.5 cell death in 2-week culture. JTK-853 suppresses the drug-resistant colony formation in the genotype 1a replicon cells, and the numbers of JTK-853-resistant colonies are much lower than those of GS-9190-resistant colonies for both genotypes_[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

704.64

C₂₈H₂₃F₇N₆O₄S₂

954389-09-4

O=C([C@@H]1N(S(=O)(C2=CC=C(C(F)(F)F)C=C2)=O)CCN(C3=NC4=NC(C5CC5)=NC=C4S3)C1)NCC6=CC=C(OC(F)(F)F)C(F)=C6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ando I, et al. JTK-853, a novel non-nucleoside hepatitis C virus polymerase inhibitor, demonstrates a high genetic barrier to resistance in vitro. Intervirology. 2013;56(5):302-9.  [Content Brief]